Insight

Incorporation of immunotherapy in the management of early-stage ER+ Breast Cancer

Collage photo of Guilherme Nader-Marta, Adrienne Waks, Sara Tolaney, Erica Mayer

Nov 10, 2024, 16:37

Incorporation of immunotherapy in the management of early-stage ER+ Breast Cancer

A recent paper by Guilherme Nader-Marta, Clinical Fellow at Dana-Farber Cancer Institute, was mentioned by Dana-Farber’s Breast Oncology Center on X:

“Check out this new editorial in ESMO Open on the incorporation of immunotherapy in the management of early-stage estrogen receptor-positive Breast Cancer.”

“Incorporating immunotherapy in the management of early-stage estrogen receptor-positive breast cancer”

Authors: Guilherme Nader-Marta, Adrienne Waks, Sara Tolaney, Erica Mayer.

Posts featuring Dana-Farber’s Breast Oncology Center

Adrienne Waks cancer Dana-Farber’s Breast Oncology Center ER+ breast cancer Erica Mayer ESMO Open Guilherme Nader Marta OncoDaily Oncology Sara Tolaney

Esophageal Cancer: Symptoms, Causes, Stages, Diagnosis & Treatment

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Special Coverage